The field of exosome-based therapeutics is expanding rapidly, with over 70 companies and 80+ pipeline therapies targeting a wide range of diseases, including cancer, neurodegenerative disorders, and inflammatory conditions. Exosomes are small vesicles that facilitate cell-to-cell communication by delivering proteins, lipids, and nucleic acids. Their natural ability to cross biological barriers, such as the blood-brain barrier, makes them promising drug delivery vehicles. Companies like Evox Therapeutics and Coya Therapeutics are engineering exosomes to deliver targeted therapies, while firms like Capricor Therapeutics and EXO Biologics are advancing clinical programs in cardiovascular, neonatal, and COVID-19-related applications. Aegle Therapeutics and Aruna Bio are also pushing forward trials in dermatology and CNS diseases, respectively. Market interest is surging, driven by diagnostic tools like Exosome Diagnostics’ ExoDx Prostate Test and manufacturing partnerships aimed at scaling production. Despite regulatory and cost challenges, early clinical data show high safety and therapeutic promise. With over 388 clinical trials underway and significant investments from pharmaceutical giants, exosomes are emerging as a transformative platform in both drug delivery and diagnostics, potentially reshaping the future of precision medicine.
Source:
https://www.geneonline.com/exosomes-what-they-do-and-whos-doing-what/
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
